Henlius’s Serplulimab Could Offer First Chemo-Free Adjuvant Option In Perioperative Gastric Cancer

 
• By Dexter Jie Yan
  
Roughly two-thirds of the annually 400,000 new gastric cancer cases in China will be suitable for perioperative treatments. (Shutterstock)

More from Clinical Trials

More from R&D